How many investments has SV Health Investors made?

SV Health Investors has 200 tracked investments, 3 of which have exited via acquisition or IPO, including 4 dated in the last 24 months.

What stage does SV Health Investors invest at?

SV Health Investors invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is SV Health Investors's typical check size?

SV Health Investors typically writes checks of $1M – $20M.

What sectors does SV Health Investors focus on?

SV Health Investors focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.

Where is SV Health Investors located?

SV Health Investors is headquartered in Boston, US.

Does SV Health Investors lead rounds?

Yes, SV Health Investors leads investment rounds.

Who does SV Health Investors co-invest with?

SV Health Investors most often shares deals with MRL Ventures Fund, Sanofi Ventures, Ascension Ventures, among 115 tracked co-investors.

SV Health Investors

Venture capital

Boston · Pre-Seed–Late Stage · 30 people tracked

Also known as SV HEALTH INVESTORS, LLC · SV HEALTH MANAGERS LLP

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

SV Health Investors pursues a proven, adaptable strategy for selecting healthcare investments and creating value. The firm invests across different stages, geographic regions and sectors, with particular expertise in biotechnology, dementia, medical devices, and healthcare services. It emphasizes a long track record of consistent performance built over decades, positioning itself to respond to the evolving demands of the healthcare industry.

Invests inBiotech Digital Health Healthtech Longevity Medical Devices Boston Europe Global London North America United Kingdom United States

Source: firm website, verified Aug 27, 2026.

Stage

Pre-Seed–Late Stage

Check

$1M – $20M

Boston, Massachusetts, US

Leads rounds

Leads

Instruments

Equity

Founded

2013

Last 12 months

4 investments

AUM

$1.1B

VC funds

Tracked investments

215

Team · 30 people

from the firm's website & curated & public directories

Aaron Sandoski· MCF Partner· Greater Bostonin

Partner on the Medtech Convergence Fund team.

a•••@norwichventures.comreveal

Greg Madden· Managing Partner· Boston, Massachusettsin

Managing Partner working across Medtech and Healthcare Growth investing.

g•••@svhealthinvestors.comreveal

Paul LaViolette· Managing Partner· Boston, Massachusettsin

Managing Partner focused on the firm's Medtech investing.

p•••@svhealthinvestors.comreveal

A.J. Rossi· Partner· Boston, Massachusetts, United States

a•••@svhealthinvestors.comreveal

Brent Faduski· Chief Financial Officer, Chief Compliance Officer and Partner· Winchesterin

Brent Faduski is CFO, Chief Compliance Officer, and Partner at SV Health Investors, which he joined in 2008, overseeing the firm's finance and accounting functions. He previously served as Controller at CMGI @Ventures and as a Senior Associate in the Technology Group at PricewaterhouseCoopers, where he worked with early-stage venture-backed companies and venture funds.

b•••@svhealthinvestors.comreveal

Kate Bingham· Managing Partner· London, England, United Kingdomin

Kate Bingham co-leads the biotech franchise at SV Health Investors, focusing on drug discovery and development companies across the UK, EU, and US, and has led many of the firm's company-creation investments. She chaired the UK Vaccine Taskforce, for which she was awarded a DBE in 2021, and holds a first class degree in Biochemistry from the University of Oxford and an MBA from Harvard Business School. She also serves on the boards of the Francis Crick Institute and ARIA.

k•••@svhealthinvestors.comreveal

Michael Balmuth· Managing Partner· Boston, Massachusettsin

Michael Balmuth joined SV Health Investors in 2014, where he focuses on digital health and healthcare technology services, including provider and payer technology, telehealth, healthcare analytics, and pharmaceutical/clinical trial software. He previously held operating roles in healthcare technology and spent over 20 years in growth equity investing, including as a General Partner at Summit Partners and as head of healthcare IT investments at Edison Partners, along with earlier leadership roles at IBM. He holds an AB in Engineering Sciences from Dartmouth College and an MBA from Harvard Business School.

m•••@svhealthinvestors.comreveal

Mike Ross· Partner· San Mateo, Californiain

Mike Ross joined SV Health Investors as a Venture Partner in 2001 and became Managing Partner in 2002, where he leads biotech investments and activities in the US and co-leads the firm's biotech franchise. Before SV, he spent 13 years at Genentech as its tenth employee, holding roles including Vice President of Development and Vice President of Medicinal and Biomolecular Chemistry, and was Founding CEO of Arris Pharmaceutical. He holds an AB from Dartmouth College, a PhD in Chemistry from Caltech, and completed an NIH Post-Doctoral Fellowship in Molecular Biology at Harvard.

m•••@svhealthinvestors.comreveal

Nikola Trbovic· Managing Partner, Biotech team· New York City Metropolitan Areain

Nikola Trbovic joined SV Health Investors in 2022 as a Managing Partner on the Biotech team. He was previously a Partner at Pfizer Ventures, where he invested in emerging companies developing new medicines, and earlier held roles in R&D technology investments, R&D strategy, and early clinical portfolio management at Pfizer. Before Pfizer, he was an Associate Principal at McKinsey & Co. in the Pharmaceuticals Practice, and he holds a PhD in Biochemistry and Molecular Biophysics from Columbia University and a Diplom in Biochemistry from Goethe University Frankfurt.

n•••@svhealthinvestors.comreveal

Tom Flynn· Managing Partner· Boston, Massachusettsin

Tom Flynn invests in growing health care companies with a primary focus on health care services, including outpatient provider services and clinician-support outsourcing businesses. Before joining SV Health Investors, he was a partner at healthcare growth capital investor Ferrer Freeman & Co. and earlier held investing roles at GE Capital and Prudential Investment Corporation. He holds an AB in Economics from Holy Cross College and an MBA from Harvard Business School.

t•••@svhealthinvestors.comreveal

Jamil Beg· Partner· Cambridge, Massachusettsin

Magnus Hildingsson· Partner· Greater Sydney Areain

m•••@pemba.com.aureveal

Nikola· Managing Partner· New York City Metropolitan Area

Founding partner of Apiary Capital, a UK private equity firm focused on business, financial, technology, education and healthcare services. Previously COO at Bowmark Capital and Duke Street and a founding partner at Park Square Capital.

Robert Haybittel· Chief Financial Officer and Partner· Greater Sydney Areain

r•••@pemba.com.aureveal

Sasa Vucinic· Managing Partner· South Koreain

Sasa chairs NBM's Investment Committee. He previously co-founded and led the Media Development Loan Fund, a mission-driven fund providing debt and equity financing to independent media in the developing world, deploying USD 100 million over 16 years. Earlier he was a journalist in Yugoslavia, serving as the first CEO of Radio B-92 in Belgrade and Editor in Chief of the magazine NON.

Shana Hudes· Managing Partner· Francein

s•••@iris.vcreveal

Christian Jung· Partner· London, England, United Kingdomin

c•••@svhealthinvestors.comreveal

Miles Gerson· Partner· USAin 𝕏

Miles Gerson joined SV Health Investors as a partner in 2026 and co-leads the firm's Dementia Discovery Fund (DDF). He previously headed Takeda Ventures, where he oversaw a portfolio of more than 60 private and public life sciences investments and led the corporate venture group's global investment strategy, and also served on an interim basis as Takeda's Head of GI Business Development. Earlier in his career he was in founding management of early-stage companies and led investment diligence for venture and private equity firms in the US and Europe. He holds a JD/MBA from the University of Wisconsin-Madison and Bachelor's and Master's degrees in Neuroscience & Behavioral Studies from Wesleyan University.

Charles Dunn· Principal· Londonin

Charles Dunn joined SV Health Investors in 2018 as a Principal on the biotech team, where he helps form and fund companies developing new medicines across early creation to later-stage public and private opportunities. Before SV he qualified as an ACA after three years at Deloitte serving Life Sciences clients, and has an academic background in human genetics and molecular biology from UCL.

c•••@svhealthinvestors.comreveal

Dirk Landgraf· Principal· Boston, Massachusettsin

Dirk Landgraf joined SV Health Investors in 2020 and is a Principal on the Dementia Discovery Fund (DDF) team, where he helps form and fund companies developing new medicines for dementia and supports DDF portfolio companies with due diligence and strategic, business development, and operational needs. Before SV, he was an Associate Director in the External Innovation group at Biogen in Cambridge, MA, evaluating business development opportunities across neurological therapeutic areas, and earlier was a Postdoctoral Fellow in Susan Lindquist's lab at the Whitehead Institute at MIT. He holds a PhD from Harvard University's Department of Systems Biology at Harvard Medical School and BSc and MSc degrees in Biochemistry from the Technical University of Munich.

Hannah Maunder· Investor Relations and Communications Associate· United Kingdomin

Serves as the firm's press contact, handling investor relations and communications.

h•••@svhealthinvestors.comreveal

Alex Badamchi-Zadeh· Senior Associate· Londonin

Alex Badamchi-Zadeh is a biotech investor at SV Health Investors, managing positions across the SV7 Impact Medicine Fund, Biotech Crossover Opportunities Fund, and SV8 Bio Fund, and serves as an investment committee member for Cancer Research Horizons. Previously, he held business development and strategy roles at Xilio Therapeutics, a NASDAQ-listed immuno-oncology company, and worked as a life science strategy consultant at L.E.K. Consulting. His background includes immunology research at Harvard Medical School, Imperial College London, and the University of Oxford, with publications in Nature, Science Immunology, and In Vivo.

a•••@svhealthinvestors.comreveal

Andrew Cappetta· Vice President· Bostonin

Andrew Cappetta joined SV Health Investors in 2022 as an Associate on the Healthcare Growth Team and advanced to Senior Associate in 2024 and Vice President in 2025. Before SV, he worked on Thermo Fisher Scientific's Corporate Development team, focusing on M&A of healthcare and life science companies, where he executed two transactions totaling $550 million. He holds a B.S. in Business Administration: Finance from the University of New Hampshire.

a•••@svhealthinvestors.comreveal

Eugene Hill· Investor· Boston, Massachusettsin

Gene Hill joined SV Health Investors in 1999 and focuses on health care services and healthcare IT services investments. Before SV, he spent five years as a Partner at Accel Partners in Palo Alto, where he handled early-stage healthcare service and HCIT investments, and previously held senior management roles including President of Behavioral Health at United HealthCare Corporation, CEO and President of US Behavioral Health, and President and Chairman of Sierra Health and Life Insurance Company. He holds a BA from Middlebury College and an MBA from Boston University.

e•••@svhealthinvestors.comreveal

Freya Easton· Associate

f•••@svhealthinvestors.comreveal

Alan Foster· Vice President· San Mateo, California, United Statesin

Alan Foster joined TeleSoft in 2004 and has over 25 years of experience in venture capital, engineering, and product management. As Managing Director he focuses on semiconductors, systems, and software investments, and has served on or observed the boards of VoiceObjects, Education.com, and Calient Technologies.

a•••@telesoftvc.comreveal

Amer Ramzan· Vice President· Copenhagen, Capital Region of Denmark, Denmarkin

Leads Promentum, combining top-tier consulting experience with a background in boards, advisory and venture capital; his role is to anchor quality and cohesion across the platform.

a•••@promentumequity.comreveal

Georgia Frost· Vice President· UKin

Georgia Frost· Vice President· London Area, United Kingdomin

g•••@svhealthinvestors.comreveal

Tim Harris· Vice President· USAin

Founder mafia

3 people who came through SV Health Investors went on to found or lead other companies.

Jamil BegPartnerFounded Nido Biosciences +1 Jonathan BehrPartnerFounded Tilos Therapeutics +1 Olivia CavlanInvestment PrincipalFounded Alchemab Therapeutics

What they invest in

from 78 of 215 portfolio companies

Healthtech ×59Biotech ×47Medical Devices ×39Digital Health ×20Deep Tech ×11AI & Machine Learning ×9Hardware ×8Advanced Manufacturing ×2

HQs:United States×59United Kingdom×4Canada×1Germany×1Ireland×1

Who they back

founder profiles across 34 portfolio companies

50%

solo founders

17 of 34 mapped founding teams

10%

repeat founders

of 10 founders with career history

~7 yrs

old at investment

median across 10 dated deals

Founding team size:solo founder×172 founders×113 founders×14+ founders×5

Where their founders studiedfrom 10 founders with education data

The Hebrew University of Jerusalem ×2

Where their founders worked beforefrom 10 founders with career history

Alzheimer's Research UK ×2Pfizer ×2UCL ×2

Investments · 215 tracked

founders shown can be your intro path

By year:2026 · 3 2025 · 5 2024 · 2 2022 · 1 2020 · 1 2019 · 1 2018 · 2 2017 · 1 2016 · 5 2015 · 1 2014 · 2 2012 · 125 dated

AdaptHealthNASDAQ: AHCO

Co-investorsOne Equity Partners

Alectoralector.com in 𝕏NASDAQ: ALECSep 2015

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

Arnon Rosenthal(Ph.D.)Tillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in

BoardCarl Gordon(Director)Terry McGuire(Director)in

Co-investorsForesite Capital Mission Bay Capital Mission Biocapital MRL Ventures Fund Polaris Partners

American Well inNYSE: AMWL

Enabling telemedicine and digital health

HealthtechBoston, US

Ido Schoenberg(Executive Officer, Director)inRoy Schoenberg(Executive Officer, Director)inJames Malone(Executive Officer)inBradford F. Gay(Executive Officer)

Co-investorsHanaco Venture Capital Martin Ventures

Cytomed TherapeuticsNASDAQ: GDTC

Insuletinsulet.com inNASDAQ: PODD

Insulet develops the Omnipod, a tubeless, wearable, disposable insulin delivery Pod, along with automated insulin delivery systems for people managing insulin-dependent diabetes.

Digital HealthHardwareHealthtechMedical DevicesActon, US

Co-investorsWinklevoss Capital

Xilio Therapeuticsxiliotx.com inNASDAQ: XLO

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)

Co-investorsBain Capital Life Sciences Bay City Capital F-Prime Capital M Ventures MRL Ventures Fund RA Capital +4 more

Spectrawavespectrawave.com in 𝕏Sep 2024✓ verified

SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.

AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US

Eman Namati(President & CEO)inGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)in

Board seatPaul LaViolette· per SEC Form D

Co-investorsLumira Ventures S3 Ventures Deerfield Management Company Johnson & Johnson Innovation – JJDC

Alchemab Therapeuticsalchemab.com in 𝕏✓ verified

Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.

AI & Machine LearningBiotechDeep TechHealthtech

Jane Osbourn(Chief Executive Officer)

Co-investorsDCVC Bio RA Capital Dementia Discovery Fund Lightstone Ventures Ono Venture Investment, Inc.DCVC (Data Collective)

Draig Therapeuticsdraigtherapeutics.com in✓ verified

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.

BiotechDeep TechDigital HealthMedical DevicesCardiff, GB

John Atack(Head of Biology & Founder)inSimon Ward(Chief Scientific Officer & Founder)in

PartnerCharles Dunn· led

Co-investorsAccess Biotechnology Canaan Partners Sanofi Ventures SR One Capital Management British Business Bank Janus Henderson Investors

Dualitas Therapeuticsdualitastx.com inJul 2025✓ verified

Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.

BiotechDeep TechSouth San Francisco, US

Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)Greg Lazar(Co-Founder & Chief Scientific Officer)Richard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)

BoardAlicia Levey(Director)Michael Ross(Director)

Co-investorsQiming Venture Partners Versant Ventures Alexandria Dementia Discovery Fund Qiming Healthcare Qiming Venture Partners USA

Ebt Medicalebtmedical.com in 𝕏✓ verified

EBT Medical develops neuromodulation technologies targeting the Saphenous nerve to treat pelvic health disorders, particularly overactive bladder.

BiotechMedical Devices

Paul Yoo(Co-founder, President & Chief Scientific Officer)Sasha John(Co-founder and Chief Innovation Officer)inKeith R Carlton(Chief Executive Officer)

Co-investorsGenesys Capital Toronto Innovation Acceleration Partners

Harness Therapeutics Ltdharnesstx.com in✓ verified

Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets.

BiotechHealthtech

Jan Thirkettle(CEO Director)

Co-investorsEpidarex Capital Ono Venture Investment, Inc.Dementia Discovery Fund

Mestagmestagtherapeutics.com in 𝕏✓ verified

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.

AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB

Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)Soumya Raychaudhuri(Founder)David A. Tuveson(Founder)Susan Hill(Chief Executive Officer)

Co-investorsForbion GV (Google Ventures)Northpond Ventures

Mestag Therapeuticsmestagtx.com in 𝕏✓ verified

Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.

AI & Machine LearningBiotechHealthtech

Susan Hill(Founder & Chief Executive Officer)Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)Soumya Raychaudhuri(Founder)David A. Tuveson(Founder)

Co-investorsGV (Google Ventures)Forbion Johnson & Johnson Innovation – JJDC Northpond Ventures

NRG Therapeuticsnrgtherapeutics.com in✓ verified

NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.

BiotechHealthtechLongevity

Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in

BoardJonathan Savidge(Independent Non Executive Chair)

Co-investorsCriteria Bio Ventures Novartis Venture Fund British Business Bank M Ventures Dementia Discovery Fund

Packaging Compliance Labspkgcompliance.com in✓ verified

Packaging Compliance Labs is an industry leader providing sterile packaging solutions, design validation, and contract packaging services for medical device and life sciences manufacturers.

Advanced ManufacturingEnterprise SoftwareMedical DevicesSaaSGrand Rapids, US

Matthew Lapham(CEO & Co-Founder)

Sitryxsitryx.com in 𝕏✓ verified

Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.

BiotechDeep TechHealthtech

Co-investorsLongwood Fund Oxford Science Enterprises Sofinnova Partners

Therini Biotherinibio.com in✓ verified

Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.

BiotechDigital HealthHealthtechMedical DevicesSacramento, US

Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in

BoardOlga Danilchanka(Director)Laia Crespo-Martin(Director)

Co-investorsMRL Ventures Fund Sanofi Ventures Angelini Ventures Mitsui Global Investment Apollo Health Ventures Dementia Discovery Fund +1 more

Axon Therapiesaxontherapies.comApr 2016SEC filingmedium confidence

Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF).

HealthtechMedical DevicesNew York, US

Howard R. Levin(Executive Officer, Director)Mark Gelfand(Executive Officer)

Board seatPaul LaViolette· per SEC Form D · $2M raise · filed Apr 2016

Co-investorsDeerfield Management Company

CardioFocuscardiofocus.com in 𝕏May 2016

CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control.

BiotechHealthtechMedical DevicesMarlborough, US

Lauren Jennings(Executive Officer)Warren Clark(Executive Officer)Stephen Sagon(Executive Officer, Director)Anjie Roldan(Executive Officer)inWarren R. Clark III(Executive Officer)Stephan S. Ogilvie(CEO)in

Board seatPaul LaViolette· per SEC Form D

Co-investorsBioBrit

Corvia MedicalJun 2025SEC filingmedium confidence

Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.

BiotechTewksbury, US

George J. Fazio(Executive Officer, Director)Dan B. Curtis(Executive Officer)

BoardKevin Gillis(Director)inGerald Brunk(Director)inIrit Yaniv(Director)

Board seatPaul LaViolette· per SEC Form D · $11.1M raise · filed Jun 2025

Co-investorsAccelmed Partners General Catalyst Lumira Ventures Third Rock Ventures

Csa Medical Increjuvenair.com inJun 2026

RejuvenAir, developed by CSA Medical, is a bronchoscopic cryosurgical device that sprays metered doses of liquid nitrogen to destroy damaged airway cells and treat the underlying cause of COPD with Chronic Bronchitis.

HealthtechMedical DevicesLutherville, US

Ellen Sheets(Executive Officer, Director)inIan J. Vawter(Executive Officer)Steven Schaefer(Executive Officer)William Floyd(Executive Officer, Director)inVincent Owens(Director)Richard Kent(Director)

Board seatPaul LaViolette· per SEC Form D

Co-investorsAscension Ventures First Analysis

Direct Flow MedicalMar 2016

HealthtechSanta Rosa, US

Dan Rose(Executive Officer)Gordon Bishop(Executive Officer, Director)David Boyle(Executive Officer)Dan T. Lemaitre(Executive Officer, Director)Chris Richardson(Executive Officer)

BoardYuval Binur(Director)

Board seatPaul LaViolette· per SEC Form D

Co-investorsFOUNDATION MEDICAL PARTNERS New Leaf Venture Partners

Endotronixendotronix.com in 𝕏Jul 2016

Endotronix develops the Cordella PA Sensor and Heart Failure System, an FDA-approved implantable pulmonary artery pressure sensor and remote monitoring platform for managing patients with NYHA class III heart failure.

Digital HealthHealthtechMedical DevicesWoodridge, US

Harry Rowland(Executive Officer, Director)Anthony I Nunez(Executive Officer, Director)Anthony A. Nunez(Executive Officer, Director)Anthony Nunez(Founder)in

BoardJonathan Jonas(Director)Raymond S. Barrett, Jr.(Director)

Board seatPaul LaViolette· per SEC Form D

Co-investorsBioventures Investors Jumpstart Ventures Lumira Ventures OSF Ventures Seroba Life Sciences

Lunair Medicallunairmedical.com inAug 2025

Lunair Medical develops an implantable closed-loop system that senses respiration and stimulates the phrenic nerve to treat moderate-to-severe sleep apnea, avoiding masks, mouthpieces, and wearables.

Digital HealthHealthtechMedical DevicesMinneapolis, US

Mark Christopherson(Executive Officer, Director)inHoward Levin(Director)

BoardDavid Neustaedter(Director)Michael Hurley(Director)

Board seatPaul LaViolette· per SEC Form D

Ocular Therapeutix Nasdoculocutx.com in 𝕏Mar 2019

Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions.

BiotechDigital HealthHealthtechMedical DevicesBedford, US

Amarpreet Sawhney(Director)Kevin Hanley(Executive Officer)Michael Goldstein(Executive Officer)inDaniel Bollag(Executive Officer)Antony Mattessich(Executive Officer, Director)inDonald Notman(Executive Officer)

Board seatCharles Warden· per SEC Form D

Co-investorsAscension Ventures Sofinnova Ventures Top Corner Capital Agent Capital

SkylitMay 2018SEC filingmedium confidence

HealthtechSan Diego, US

Martyn Gross(Executive Officer, Director)Kathy Scott(Executive Officer)

BoardJohn Buhler(Director)Rex Bright(Director)David Hale(Director)

Board seatPaul LaViolette· per SEC Form D · $43M raise · filed Oct 2021

Co-investors7wire Ventures

Stimwave Technologiesstimwave.comAug 2020SEC filingmedium confidence

BiotechHealthtechPompano Beach, US

Laura Tyler Perryman(Director)Regina Groves(Executive Officer, Director)Virginia Sullivan(Executive Officer)Marc Loev(Director)Richard Chen Mao(Director)Gary Perryman(Director)

Board seatPaul LaViolette· per SEC Form D · $8M raise · filed Sep 2020

Co-investorsEmergent Medical Partners, LLP

TransEnterixtransenterix.com inSep 2017

Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.

AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US

Anthony Fernando(Executive Officer)inTodd M. Pope(Executive Officer, Director)Joseph P Slattery(Executive Officer)James J. Martin(Executive Officer)Charles J. Filipi(Executive Officer, Director)Jeffrey G. Spragens(Executive Officer, Director)

Board seatPaul LaViolette· per SEC Form D

Co-investorsAisling Capital Quaker BioVentures SV Life Sciences

ValenTxvalentx.comJul 2014

BiotechMaple Grove, US

JON PATRICK ST. GERMAIN(Executive Officer)DAVID KRENN(Executive Officer)JOHANN NEISZ(Executive Officer, Director)

BoardMARY LINCOLN CAMPBELL(Director)MITCHELL DANN(Director)PAUL A. LAVIOLETTE(Director)in

Board seatPaul LaViolette· per SEC Form D

Co-investorsKaiser Permanente Ventures

0 2 AstronauTxastronautx.bio in

Co-investorsMPM BioImpact Novartis Venture Fund UCL Technology Fund

Accelecare Holdings

Achillion Pharmaceuticals

Co-investorsPappas Capital

Adimabadimab.com in

Adimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system.

AI & Machine LearningBiotechDeep TechVermont, US

Co-investorsGrandBanks Capital LaunchCapital Lux Capital Premji Invest Mithril Capital Management OrbiMed +1 more

AdvanCelladvancell.com.au inJun 2026

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsBain Capital Life Sciences Catalio Capital Management, LP Proto Axiom Tenmile Abingworth Ally Bridge Group +2 more

AeroCare Holdings, Inc.

Affinium Pharmaceuticals

Alantos Pharmaceuticals

Alchemab

Co-investorsRA Capital

Aligned Telehealth IncJul 2016

HealthtechCalabasas, US

Nitin Nanda, M.D.(Executive Officer, Director)Nitin Nanda(Executive Officer, Director)

BoardMichael Balmuth(Became Director as of July 8, 2016)inJohn Eugene Hill(Became Director as of July 8, 2016)Deepak Chopra(Director)Vikram Marla(Resigned as director July 8, 2016)

Allegiance Hospice Group

AllianceCare

Allos Therapeutics

Ally Bridgeally-bridge.com

Ally Bridge Group is a healthcare investment management firm investing across the global life sciences industry through complementary private equity and public equity strategies.

BiotechHealthtechMedical DevicesNew York, US

Frank Yu(Founder, Chief Executive Officer, Chief Investment Officer)in

Alpheus Medicalalpheusmedical.com in

Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.

BiotechHealthtechMedical DevicesChanhassen, US

Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)

BoardKlaus Veitinger(Director)inImran Eba(Executive Officer)in

Co-investorsOrbiMed HealthQuest Capital Samsara BioCapital Action Potential Venture Capital Ltd.

Altura Medical

Amphistaamphista.com in 𝕏

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)Martin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)

Co-investorsAdvent Life Sciences Novartis Venture Fund Dementia Discovery Fund European Investment Fund Forbion Gilde Healthcare +1 more

Aptiv Solutions

AqueSysAcquired

AqueSys was a clinical-stage ophthalmic device company behind the XEN Gel/XEN45 glaucoma shunt, acquired by Allergan in 2015.

Co-investorsRho Capital Partners Rho Ventures

Argonaut Technologies

Arsanis Biosciences

Artios Pharmaartios.com in 𝕏

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.

BiotechHealthtechMedical Devices

Co-investorsAndera Partners M Ventures Novartis Venture Fund Pfizer Venture Investments RA Capital Sofinnova Partners

Atopix Therapeutics Limited

Autifony Therapeutics

Co-investorsPfizer Venture Investments

Auxilium Pharmaceuticals

Avitideavitide.com inacquired by Repligen

Advanced ManufacturingBiotechHardwareLebanon, US

Tillman Gerngross(Director)Errik Anderson(Director)Warren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)

Co-investorsOrbiMed Mithril Capital Management Sands Capital Ventures SV Life Sciences

AvroBio, Inctheavrobio.org in 𝕏

AVROBIO develops ex vivo lentiviral vector-based hematopoietic stem cell gene therapies to treat lysosomal disorders by permanently integrating therapeutic genes into patient stem cells manufactured outside the body.

BiotechDigital HealthHealthtechMedical Devices

Axys Pharmaceuticals

Bardybardydx.com inAcquired

BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.

Digital HealthHealthtechMedical DevicesSeattle, US

Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)

Co-investorsAPERTURE Venture Partners Aphelion Capital Ascension Ventures Lumira Ventures RC Capital Rex Health Ventures +1 more

Bicyclebicycletherapeutics.com in 𝕏May 2024

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge

GREGORY WINTER(Director)KEVIN LEE(Executive Officer, Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)

Co-investorsAhren Innovation Capital Astellas Venture Management LLC Cambridge Innovation Capital Longwood Fund SR One Capital Management Vertex Ventures HC

BioAge

Biotechnology company developing drugs to treat aging and associated diseases

Co-investorsFelicis Ventures OUP (Osage University Partners)

BioCore Holdings

BioCore Holdings (BioClinica)

Brixtonbiobrixtonbio.com

Brixton Bio develops Reneurx therapy, a treatment aimed at providing long-lasting pain relief for up to six months from a single administration.

BiotechMedical Devices

Charles Sidoti(Founder)in

Co-investorsAngel Physicians Fund Excelestar Ventures FemHealth Ventures Schooner Capital

Broadlane

Cadent Technologies

Carawaycarawaytx.com in 𝕏acquired by Merck

Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases.

BiotechHealthtech

Co-investorsEisai Innovation, Inc.MRL Ventures Fund

Cardiac Support Systems

CardioKinetixDec 2014

HealthtechMenlo Park, US

Brett Hale(Executive Officer)Maria Sainz(Executive Officer, Director)

BoardLou Bock(Director)Jeani Delagardelle(Director)Casey Tansey(Director)Rodney Ferguson(Director)

Co-investorsArcher Capital Group Archer Venture Capital New Leaf Venture Partners SV Life Sciences

CardioMind

CarePredict

Celerioncelerion.com in

Celerion is a contract research organization specializing in early phase clinical drug development, providing bioanalytical services and laboratory testing that generate clinical data for pharmaceutical clients.

BiotechDigital HealthHealthtechMedical DevicesLincoln, US

Co-investorsH.I.G. Capital H.I.G. HealthBridge Partners

Cellutions

Cellzome Limited

Centauri Holdings

Scottsdale, US

Michelle Miller(Executive Officer)Adam T. Miller(Executive Officer, Director)Michael McNelis(Executive Officer)Glenn M. Parker(Executive Officer, Director)

BoardJames J. Quagliaroli(Member of the Management Board of Issuer)in

Co-investorsSilversmith Capital Partners

Cerebral Vascular Applications

Cerevancecerevance.com in 𝕏

Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US

Craig Thompson(Chief Executive Officer)Sagar Vaidya(Chief Medical Officer)Carrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)Ottavio V. Vitolo(Chief Medical Officer)

Co-investorsForesite Capital GV (Google Ventures)Dementia Discovery Fund SV Life Sciences Dementia Discovery Lightstone Ventures +2 more

CHF Solutions

Cibiem

Cognis Holding

Concentric Medical

Confluent Surgical, Inc.confluentsurgical.com

Co-investorsAscension Ventures HLM Venture Partners

Convergence Pharmaceuticals

Coral Therapeutics

CoreLab Partners

CRI Worldwide

Cumulus

Doctors of Physical Therapy

Dualitas

EasyChem

eMed Technologiesemedtc.com in

EMED makes infusion pump systems and subcutaneous delivery devices for patients requiring immunoglobulin therapy and other biologics.

Digital HealthHardwareHealthtechMedical Devices

Phil Parvin MBAin

Endlyz

Entellus

EPIVAX, INC.epivax.com

Annie De Groot MD(Founder)inRich-Henry Schabowsky, PhD, JDin

Ervaxx Limited

ESBATech

Eunoe

Euro Dentalversand

Euro Dentalversand Holding

EUSA Pharma

Co-investorsAdvent Life Sciences Essex Woodlands Healthcare Partners

Evelo Biosciences in

BiotechCambridge, US

Jennifer Glennon(Executive Officer)inBalkrishan (Simba) Gill, Ph.D.(Executive Officer, Director)Duncan McHale(Executive Officer)inWilliam DeVaul(Executive Officer)inMark Bodmer, Ph.D.(Executive Officer)

BoardNoubar B. Afeyan, Ph.D.(Director)

Co-investorsFlagship Pioneering Kaiser Permanente Ventures

Evidation Healthevidation.com in 𝕏

Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions.

BiotechData & InfrastructureDigital HealthHealthtechSan Francisco, US

Christine Lemke(Executive Officer, Director)Deborah Kilpatrick(Executive Officer, Director)Leslie Oley Wilberforcein

BoardDavid Fleshman(Director)Rowan Chapman(Director)

Co-investorsAsset Management Company B Capital Group B4 Capital Cross Creek Advisors Fresco Capital G Squared +4 more

EyeBioacquired by Merck

Global company developing next-generation eye disease therapies; acquired by Merck & Co.

Co-investorsBain Capital Life Sciences Jeito Capital MRL Ventures Fund

Eyetech Pharmaceuticals

Geltex Pharmaceuticals

Co-investorsNew Enterprise Associates (NEA)

General Surgical Innovations

Genosis

GlycoFi Inc

Halscion

Health Payment Systems

Healthify

Heritage Health Systems

HighTop Health

Homecare Homebasehchb.com

IHG Holdings

Ikano Therapeutics

Imbriaimbria.com inNov 2025 · $57.5M

Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.

BiotechDigital Health

Alvin Shih(CEO)Albert M. Kim(Chief Medical Officer)

Co-investorsAN Venture Partners RA Capital Sanofi Ventures Catalio Capital Management

Imbria

Imbria PharmaceuticalsApr 2025 · $57.5M

BiotechBoston, US

Pavan Cheruvu(Director)Alvin Shih(Executive Officer, Director)Komal Joshi(Executive Officer)Pieter Boelhouwer(Director)David-Alexandre C. Gros(Executive Officer, Director)

BoardCharles Dunn(Director)

Co-investorsCatalio Capital Management RA Capital

Incyte Pharmaceuticals

ISG Holdings

JC Nationwide

Jet Health

Fort Worth, US

Stacie Bratcher(Executive Officer)Jim Douthitt(Mr. Douthitt is the Secretary of the Issuer.)

BoardJames Glynn(Director)Thomas Flynn(Director)inStephen Griggs(Director)Liston Thomas(Director)

KalVista Pharmaceuticals

Co-investorsFrazier Life Sciences Longwood Fund

Kinetix Pharmaceuticals

KuDOS Pharmaceuticals

Leal Therapeutics

Clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics for central nervous system disorders.

Leica Microsystemsleica-microsystems.com in 𝕏

Leica Microsystems manufactures optical microscopy instruments and fluorescence reagents for scientific research and diagnostics.

BiotechDeep TechHardwareHealthtechMedical DevicesWetzlar, DE

Leitersleiters.com in

Leiters Health is an FDA-registered 503B outsourcing facility that produces sterile compounded preparations for hospitals, surgery centers, and ophthalmic use.

BiotechHealthtechMedical DevicesDenver, US

Co-investorsCorewell Health Ventures Escalate Capital Partners Frazier Healthcare Partners H.I.G. Capital H.I.G. HealthBridge Partners Kaiser Permanente Ventures +2 more

LenSx Lasers Inc

LeukoSite Inc

LipoSonix

LoQus23loqus23.com in

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in

Co-investorsNovartis Venture Fund Dementia Discovery Fund Forbion

Maestro Healthcare

Mdeverywhere

MedNova

Miach Orthopaedicsmiachortho.com in

Miach Orthopaedics develops implants that help the body restore its own connective tissue, with an initial focus on treating ACL tears.

HealthtechMedical DevicesWestborough, US

Martha Murray(Founder)inChris Joyce(Executive Officer)inPatrick McBrayer(Executive Officer, Director)inSean Sansiveri(Director)Pieter Wolters(Director)

BoardMarc-Andre Marcotte(Director)

Co-investorsAmzak Health APERTURE Venture Partners Endeavour Vision

Micromass

MicroMed

BiotechHealthtechIndianapolis, US

Richard Dodson(Executive Officer, Director)James Floyd(Executive Officer, Director)Anders Weaver(Executive Officer, Director)Phillip Clem(Executive Officer, Director)

Micromet Inc

MindFrame

Misonix

Co-investors1315 Capital Sofinnova Ventures

Montara Therapeutics

Mpex Pharmaceuticals

MSTmst-sys.comMar 2026 · $40M

Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.

Media & Entertainment

Co-investorsAgate Medical Investments LP SCP Vitalife Partners Forbion GV (Google Ventures)Northpond Ventures

MyOrthos

NanoPath

NeoVistaFeb 2012

HealthtechNewark, US

John Hendrick(Executive Officer, Director)Tim Dumke(Executive Officer)

BoardStephen Martin(Director)William Link(Director)Ryan Schwarz(Director)Steven Waite(Director)

Co-investorsMPM BioImpact Oxford Finance LLC SV Life Sciences Versant Ventures

Neurogeneus

Nexan

Nimbus Therapeutics

Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.

Co-investorsAccess Biotechnology Bain Capital Life Sciences Lightstone Ventures Pfizer Venture Investments RA Capital

Nira Medicalniramedical.com in

Nira Medical consolidates independent neurology practices across the United States to improve patient access to neurological care.

Digital HealthHealthtechMedical Devices

Co-investorsSilversmith Capital Partners TRANSFORMATION CAPITAL

Nitrome Biosciences

BiotechJackson, US

Irene Griswold-Prenner(Executive Officer, Director)

BoardZach Hall(Director)Ephraim Heller(Director)William McDowell(Director)Regis Kelly(Director)

Co-investorsDementia Discovery Fund Sofinnova Partners

Nordic Consulting Partners

NovaLign

Nuwellisnuwellis.com in 𝕏

Nuwellis develops medical technology solutions for managing fluid overload in patients with cardiorenal conditions, serving clinicians and healthcare providers in inpatient and outpatient settings.

BiotechHardwareHealthtechMedical DevicesEden Prairie, US

Rob Scott(Executive Officer)Nestor Jaramillo, Jr.(Executive Officer, Director)Brian Brown(Executive Officer)David A. Rosa(Executive Officer, Director)Claudia Drayton(Executive Officer)Debra J. Kridner(Executive Officer)

Co-investorsAscension Ventures Kaiser Permanente Ventures

OMS Foundations

OncoEthix

Co-investorsAndera Partners

Onkos Surgicalonkossurgical.com in 𝕏

Onkos Surgical develops limb salvage and orthopedic reconstruction implants and systems for treating musculoskeletal cancer and complex orthopedic conditions.

HardwareHealthtechMedical DevicesParsippany, US

Patrick Treacy(Founder)inAntony Koblish(Director, Promoter)inBrad Tyler(Executive Officer)in

BoardAdele Oliva(Director)Stephen Bloch(Director)Paul Touhey(Director)

Co-investors1315 Capital Canaan Partners JSD Capital, LLC

Ophthotechophthotech.comOct 2018

BiotechNew York, US

David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)

Co-investorsSofinnova Ventures Clarus SV Life Sciences

Orchid Chemicals

Orthovita

Patient Care

Pelton & Crane

Perfuzeperfuze.com in

Perfuze develops medical devices for the treatment of acute ischemic stroke, focused on addressing unmet clinical needs in mechanical thrombectomy.

Deep TechHealthtechMedical DevicesGalway City, IE

Wayne Allen(Co-Founder, CEO, Director)inLiam Mullins(CTO and Co-founder)in

Co-investorsSeroba Life Sciences EQT Life Sciences

Phase Forward

Physicians Dialysis Inc.

Pivot Point Consultingpivotpointconsulting.com in

Pivot Point Consulting provides managed IT services, EHR consulting, strategic advisory, analytics and AI solutions, and ERP implementation services to healthcare organizations.

AI & Machine LearningEnterprise SoftwareHealthtechSaaS

Podimetricspodimetrics.com in

Podimetrics offers a remote monitoring and care program for people with complex diabetes, centered on the SmartMat device that collects foot-health data to enable early intervention and prevent complications such as amputations.

Digital HealthHealthtechMedical DevicesSomerville, US

David Linders(Executive Officer, Director)inJonathan Bloom(Executive Officer, Director)

BoardAaron Sandoski(Director)in

Co-investorsNorwich Ventures Scientific Health Development Polaris Partners Rock Health

PowderMed Ltd

Prilenia

Pulmocidepulmocide.com inDec 2022 · $52M

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.

BiotechHealthtech

Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin

Co-investorsAdjuvant Capital F-Prime Capital Jeito Capital Longwood Fund SR One Capital Management Vivo Capital +2 more

Quell Therapeutics

Clinical stage company transforming lives in immune mediated disease

Co-investorsAlbionVC Jeito Capital

Quick Study Radiol

Quralisquralis.com in 𝕏

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in

Co-investorsDroia Ventures MC Healthcare Ventures Mission Biocapital Mitsui Global Investment Sanofi Ventures Amgen Ventures +6 more

Remita Health

Rempex Pharmaceuticals

RespiVert Ltd

Ria Healthriahealth.com in 𝕏

Ria Health provides telemedicine-based treatment for alcohol and opioid use disorders, delivered by a team of physicians, nurse practitioners, and counselors.

Digital HealthHealthtechMental HealthWellness & FitnessSan Francisco, US

Bill Stapleton(CEO)

Co-investorsSOSV

Ribometrixribometrix.com

BiotechGreenville, US

Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)

BoardMike Dial(Director)in

Co-investorsIllumina Ventures M Ventures MC Healthcare Ventures Pappas Capital Dementia Discovery Fund Hatteras Venture Partners +1 more

Ricerca Biosciences

Rinat Neuroscience

Co-investorsProspect Venture Partners

Robling Medical Inc

Rondo Therapeuticsrondotx.com in

Rondo Therapeutics develops immune-engaging bispecific antibodies designed to treat solid tumors with tuned immune-activating arms and tumor-localized activity to reduce side effects.

BiotechHealthtech

Shelley Force Aldred(Chief Executive Officer & Co-Founder)Nathan Trinklein(Chief Scientific Officer & Co-Founder)

Sadra Medical

Schweigerdermschweigerderm.com in

Schweiger Dermatology Group is a dermatology practice that provides medical and cosmetic dermatological services to patients, with locations across multiple areas and handling insurance billing, co-pays, and cosmetic procedures.

Digital HealthHealthtechMedical DevicesWellness & FitnessNew York, US

Dr. Eric Schweiger

Co-investorsLLR Lnk

Shire Pharmaceuticals

Sirona Dental Systems

Sitryx Therapeutics Limited

Socios Mayores en Salud

Co-investorsHLM Venture Partners

Solexa Ltd

Spectrum Professional Services

Spinal Kineticsspinalkinetics.com in

HealthtechSunnyvale, US

Thomas Afzal(Executive Officer, Director)

BoardPeter van der Velden(Director)David Milne(Director)Dan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)

Co-investorsHLM Venture Partners Lumira Ventures SV Life Sciences

Spineology Incspineology.com in

Spineology develops minimally invasive spine surgery implants, including its flagship OptiMesh interbody fusion technology that delivers a bone graft-containing implant through a small surgical portal.

BiotechHardwareHealthtechMedical DevicesSt. Paul, US

Stephen D. Kuslich(Founder)JAMISON YOUNG(Executive Officer)inBrian Snider(Chief Executive Officer & Board Member)inSteve Nemitz(Chief Financial Officer)inAmanda Bloom(Executive Vice President, Marketing)inEmory Rooney(Executive Vice President, Sales)in

Co-investors1315 Capital RC Capital

Stimwave

Strides Arcolab

Sudo Biosudobio.com

Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.

BiotechHealthtechMedical DevicesMenlo Park, US

Jim Bristol(Director)Daniel Estes(Director)Scott Byrd(Executive Officer, Director)

Co-investorsFrazier Life Sciences Monograph Capital Partners Sanofi Ventures Dementia Discovery Fund TPG

Sun Behavioral Healthsunbehavioral.com

SUN Behavioral Health operates inpatient hospitals and home- and community-based programs providing mental health and substance use disorder treatment across a full continuum of care, from crisis stabilization to long-term recovery.

Digital HealthHealthtechMental Health

Steve Page(CEO & Founder)in

BoardEugene Hill(Director)Wilfred Jaeger(Director)David Fitzgerald(Director)Brian Murphy(Director)

Co-investorsLLR

Synarc

The Corner Pharmacy

Browse all 215 investments with full details →

▶15 more tracked companies

Third Wave TechnologiesTLC VisionTransine Therapeutics LtdTransposonTRexBioTriangle PharmaceuticalsTrimTechU S Renal Care Urgent TeamVersicorVibrato MedicalViolet Therapeutics, Inc.Vitalize Consulting SolutionsWellTheoryXimedica

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 9

IPOs and acquisitions across the tracked portfolio

AdaptHealthNASDAQ: AHCOAlectorNASDAQ: ALECAmerican WellNYSE: AMWLCytomed TherapeuticsNASDAQ: GDTCInsuletNASDAQ: PODDXilio TherapeuticsNASDAQ: XLOAvitideacq. by RepligenCarawayacq. by MerckEyeBioacq. by Merck

Portfolio news

latest coverage across their companies

Mitsubishi UFJ Asset Management Co. Ltd. Invests $26.41 Million in Insulet Corporation $PODD - Markets Daily

Insulet · themarketsdaily.com · Aug 21, 2026

Xilio Therapeutics (NASDAQ:XLO) Announces Quarterly Earnings Results - Ticker Report

Xilio Therapeutics · tickerreport.com · Aug 15, 2026

Truist raises American Well stock price target to $12 on EBITDA outlook By Investing.com

American Well · in.investing.com · Aug 13, 2026

The 19 Largest Global Startup Funding Rounds of July 2026 – AlleyWatch

AdvanCell · alleywatch.com · Aug 13, 2026

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B

Draig Therapeutics · fiercebiotech.com · Aug 12, 2026

Irvine’s new JOST Bicycle and Pedestrian Bridge raises riders over the 5 Freeway

Bicycle · ocregister.com · Aug 11, 2026

Strategy sells 1,690 BTC, raises $653M from MST... | Pluang

MST · pluang.com · Aug 10, 2026

Alector (NASDAQ:ALEC) Shares Up 7.9% – What’s Next? - Daily Political

Alector · dailypolitical.com · Jul 17, 2026

Fund performance · per public LP disclosures

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
SV Health Investors Growth Fund VII bLPs: New Mexico Educational Retirement Board	2024	—	0.0%	0.00x	0.00x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has SV Health Investors made?: SV Health Investors has 200 tracked investments, 3 of which have exited via acquisition or IPO, including 4 dated in the last 24 months.
What stage does SV Health Investors invest at?: SV Health Investors invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is SV Health Investors's typical check size?: SV Health Investors typically writes checks of $1M – $20M.
What sectors does SV Health Investors focus on?: SV Health Investors focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is SV Health Investors located?: SV Health Investors is headquartered in Boston, US.
Does SV Health Investors lead rounds?: Yes, SV Health Investors leads investment rounds.
Who does SV Health Investors co-invest with?: SV Health Investors most often shares deals with MRL Ventures Fund, Sanofi Ventures, Ascension Ventures, among 115 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Medtech Venture Capital Insights with Paul LaViolette of SV Health Investors

State of MedTech · Paul LaViolette

Co-investors · 28

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Both backed · 7

Xilio Therapeutics Alchemab Therapeutics Artios Pharma Imbria Imbria PharmaceuticalsAlchemabNimbus Therapeutics

Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.

Both backed · 7

AdvanCell Draig Therapeutics Evidation Health Imbria Quralis Sudo Bio Therini Bio

$5M

Ascension Ventures

Ascension Ventures manages capital and presents itself as an investor connected to a large health system network, referencing hundreds of acute care hospitals and a substantial employee base.

Both backed · 5

Bardy Csa Medical Inc Nuwellis Ocular Therapeutix NasdoculConfluent Surgical, Inc.

$10M – $20M

M Ventures

M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.

Both backed · 4

Xilio Therapeutics Artios Pharma NRG Therapeutics Ribometrix

$10.8M

Polaris Partners

Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.

Both backed · 3

Alector Podimetrics Quralis

$500K – $5M

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 3

Adimab Alpheus Medical Avitide

$1M – $75M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 3

Artios Pharma Nitrome Biosciences Sitryx

$540K – $27M

Dolby Family Ventures

Dolby Family Ventures is an investment firm focused on life sciences, backing companies across precision neuroscience and life sciences platforms.

Both backed · 3

Cerevance Quralis Therini Bio

Lightstone Ventures

Lightstone Ventures is a life sciences venture firm founded in 2012 that invests in biotech and medtech companies, backing founders translating scientific breakthroughs into therapies and medical technologies.

Both backed · 3

Alchemab Therapeutics CerevanceNimbus Therapeutics

7wire Ventures

7wire Ventures builds and invests in early-stage digital health companies focused on empowering informed, connected health consumers.

Both backed · 2

Skylit WellTheory

$100K – $5M

New Leaf Venture Partners

New Leaf Venture Partners is a venture capital firm investing in innovative healthcare companies.

Both backed · 2

CardioKinetix Direct Flow Medical

Silversmith Capital Partners

Silversmith Capital Partners is a growth equity firm that partners with entrepreneurs in the technology and healthcare sectors, providing capital and long-term partnership.

Both backed · 2

Centauri Holdings Nira Medical

$20M – $125M

▶16 more co-investors

B Capital Group SOSV Atlas Venture Summit Partners Third Rock Ventures Abingworth Aisling Capital McKesson Ventures Bain Capital Ventures US Venture Partners S32 Pivotal Life Sciences Sandbox Industries Omega Funds Borealis Ventures JUXTAPOSE VENTURES

Firms observed investing alongside SV Health Investors, from public investor directories. Shared companies are the overlap with SV Health Investors's recorded portfolio.

Similar investors

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Lumira Ventures

Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.

$1M – $10M

OrbiMed

$1M – $75M

Pontifax Venture Capital

Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.

$6.3M – $128M